| Xcovery is aggressively developing three promising programs
in oncology and inflammation. Xcovery's approach and experience
in kinase therapeutics facilitates rapid discovery, with
one of the shortest paths from discovery to pre-clinical
development among the industry. |
|
| Lead candidate selection for two of Xcovery's
programs will take place in 2007, with the third following
shortly in early 2008. |
|
 |
| |
|